Recent Investment Analysts’ Ratings Updates for Biohaven (BHVN)

A number of firms have modified their ratings and price targets on shares of Biohaven (NYSE: BHVN) recently:

• 1/6/2026 – Biohaven had its price target lowered by analysts at Morgan Stanley from $26.00 to $21.00. They now have an “overweight” rating on the stock.
• 12/29/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/26/2025 – Biohaven had its “market perform” rating reaffirmed by analysts at William Blair.
• 12/26/2025 – Biohaven had its “buy” rating reaffirmed by analysts at Citigroup Inc..
• 12/26/2025 – Biohaven had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
• 12/22/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/3/2025 – Biohaven was downgraded by analysts at HC Wainwright from a “buy” rating to a “neutral” rating. They now have a $11.00 price target on the stock, down previously from $30.00.
• 12/1/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Biohaven was downgraded by analysts at UBS Group AG from a “buy” rating to a “neutral” rating. They now have a $11.00 price target on the stock, down previously from $26.00.
• 11/24/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/20/2025 – Biohaven had its price target lowered by analysts at JPMorgan Chase & Co. from $47.00 to $15.00. They now have an “overweight” rating on the stock.
• 11/18/2025 – Biohaven had its price target lowered by analysts at Morgan Stanley from $54.00 to $26.00. They now have an “overweight” rating on the stock.
• 11/18/2025 – Biohaven had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $16.00 price target on the stock.
• 11/17/2025 – Biohaven had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling

In other news, Director Gregory Bailey purchased 400,000 shares of the firm’s stock in a transaction on Thursday, November 13th. The shares were bought at an average cost of $7.50 per share, with a total value of $3,000,000.00. Following the purchase, the director directly owned 2,020,071 shares of the company’s stock, valued at approximately $15,150,532.50. This trade represents a 24.69% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John W. Childs acquired 3,333,333 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was purchased at an average cost of $7.50 per share, with a total value of $24,999,997.50. Following the transaction, the director owned 5,653,904 shares of the company’s stock, valued at approximately $42,404,280. The trade was a 143.64% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 4,416,999 shares of company stock worth $33,144,833 in the last ninety days. 16.00% of the stock is currently owned by insiders.

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.